Shuttle Pharmaceuticals Holdings, INC 8-K filings

Shuttle Pharmaceuticals announced FDA approval for its Phase 2 glioblastoma trial, progress in site enrollment, and the creation of a diagnostics subsidiary.

Shuttle Pharmaceuticals Holdings, Inc. announces its CEO will present at the Planet MicroCap Showcase in Las Vegas on May 1, 2024, and has released an updated investor presentation.

Shuttle Pharmaceuticals' CEO will present at the Planet MicroCap Showcase, discussing the company's Phase 2 clinical trial for glioblastoma and plans for its subsidiary, Shuttle Diagnostics.

Shuttle Pharmaceuticals has received FDA approval for a Phase 2 clinical trial of Ropidoxuridine and is expanding into diagnostics with a new subsidiary and intellectual property licenses.

Shuttle Pharmaceuticals has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and the CEO will present at the Emerging Growth Conference.

Shuttle Pharmaceuticals plans to raise up to $4.5 million through a rights offering, with a significant portion backstopped by SRO LLC, to fund a diagnostics laboratory for prostate cancer research.

Shuttle Pharmaceuticals has acquired the PSMA-Boron invention, a potential theranostic agent for prostate cancer, from its inventors, Alan Kozikowski and Werner Tueckmantel.